Compare RNST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | EVO |
|---|---|---|
| Founded | 1904 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 568.6M |
| IPO Year | 1997 | 2007 |
| Metric | RNST | EVO |
|---|---|---|
| Price | $39.28 | $1.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $48.14 | $4.17 |
| AVG Volume (30 Days) | ★ 597.0K | 159.1K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.20 | N/A |
| Revenue Next Year | $3.25 | $20.51 |
| P/E Ratio | $21.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.04 | $1.50 |
| 52 Week High | $44.54 | $4.27 |
| Indicator | RNST | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 41.31 |
| Support Level | $39.11 | $1.50 |
| Resistance Level | $40.84 | $1.97 |
| Average True Range (ATR) | 0.75 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 42.67 | 46.00 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.